What more can you tell me about TheraVitae and VesCell™?
VesCell™ is proprietary stem cell technology currently used to treat heart disease and peripheral artery disease. It is the flagship product of TheraVitae Co. Ltd., a global leader in adult stem cell research and treatment. TheraVitae is a private company established in 2003 with corporate headquarters in Toronto, Canada. With facilities in Israel, Thailand, and Hong Kong, our more than 40 full-time research and technical staff are working to redefine medicine and bring adult stem cell treatment within the reach of the average consumer. We are committed to helping people live fuller, healthier lives. Our mission is to develop and commercialize adult stem cell therapies to treat previously incurable diseases. TheraVitae holds license to six pending U.S. patents with more than 500 claims.
TheraVitae is a biotechnology company focused on using adult stem cells from the patient’s blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell™ that is currently being used by hospitals in Thailand to treat patients with heart disease and PAD. TheraVitae is based in Bangkok, Thailand, Hong Kong and has state-of-the-art laboratory facilities in Kiryat Weizmann , Israel.
TheraVitae is a biotechnology company focused on using adult stem cells from the patient’s blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell that is currently being used by hospitals in Thailand to treat patients with heart disease and PAD. TheraVitae is based in Bangkok, Thailand, Hong Kong and has state-of-the-art laboratory facilities in Kiryat Weizmann , Israel.
